BioWorld Science

Aug. 24, 2016

View Archived Issues

Antimitotic compound leiodermatolide reduces pancreatic tumor weights in vivo

Read More

IdeS reduces HLA antibodies in kidney transplant candidates

Read More

Novel compound E-6887 shows promise for treating lupus

Read More

U.S. HHS awards contracts to support development of Zika virus diagnostic tests

Read More

Hemispherx Biopharma's NDA for rintatolimod receives approval in Argentina

Read More

Orally available peptides from Protagonist Therapeutics show promise for treating IBD

Read More

Biotron identifies new compounds in Zika program, signs agreement with NIAID

Read More

EMA validates Cempra's MAA for solithromycin

Read More

Oncology Venture updates progress of phase I trial of LiPlaCis

Read More

Innovative Targeting Solutions signs agreement with Janssen Biotech

Read More

FORMA Therapeutics describes HDAC inhibitors

Read More

Immune Therapeutics initiates Malawi study of LDN for prevention of cervical cancer

Read More

FDA grants breakthrough status to Stemline's SL-401

Read More

Cyon Therapeutics licenses Novartis' anti-PCSK9 antibody LGT-209

Read More

Temple University discovers novel 5-HT7 antagonists to treat inflammatory bowel disease

Read More

Pfizer to acquire AstraZeneca's small molecule anti-infectives business

Read More

FDA accepts Clovis' NDA for rucaparib

Read More

GlaxoSmithKline and Astex present a novel potent and reversible inhibitor of PAF acetylhydrolase

Read More

Biocardia merges with Tiger X Medical, forms new entity

Read More

AiCuris Anti-infective Cures' pritelivir achieves primary endpoint in phase I trial

Read More

Nanoantibiotics changes name to Biovie

Read More